利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.012 秒)

    DETERMINATION AND IDENTIFICATION OF ACTIVE COMPOUNDS IN A COMPOUND LIBRARY
    4.
    发明公开
    DETERMINATION AND IDENTIFICATION OF ACTIVE COMPOUNDS IN A COMPOUND LIBRARY 失效
    决心和图书馆物质活性物质的鉴定

    公开(公告)号：EP0754238A1

    公开(公告)日：1997-01-22

    申请号：EP95916181.0

    申请日：1995-04-03

    申请人： PHARMAGENICS, INC.

    发明人： BEUTEL, Bruce, A.

    IPC分类号： G01N33 ,  C07H21 ,  C07K1 ,  C12Q1

    CPC分类号： C07K1/047 ,  C07H21/00 ,  Y10S435/962

    摘要： Libraries of compounds such as nucleic acids or peptides are contacted with a target molecule and libraries that have at least one compound that binds with at least a minimum activity are determined by a reiterative process in which a change in the rate of recorvery (elimination) of compounds that bind to the target indicates that the library contains such a compound. The procedure may also be used to determine indirectly the sequence of such compound by employing sublibraries, each of which has a known entity at a known position of the compound.

    VECTORS AND VECTOR SYSTEMS INCLUDING GENES ENCODING TUMOR SUPPRESSOR PROTEINS AND PRODUCER CELLS TRANSFORMED THEREBY
    5.
    发明公开
    VECTORS AND VECTOR SYSTEMS INCLUDING GENES ENCODING TUMOR SUPPRESSOR PROTEINS AND PRODUCER CELLS TRANSFORMED THEREBY 失效
    向量和向量系统，包括基因TUMORSUPRESSORPROTEINE代码和生成细胞经变换会。

    公开(公告)号：EP0682698A1

    公开(公告)日：1995-11-22

    申请号：EP95904883.0

    申请日：1994-12-09

    申请人： PHARMAGENICS, INC.

    发明人： BEAUDRY, Gary A. ,  BERTELSEN, Arthur H. ,  SHERMAN, Michael I. ,  VOGELSTEIN, Bert

    IPC分类号： C07K14

    CPC分类号： C07K14/4746 ,  C12N2799/027

    摘要： Vectors and vector systems are embodied that include a gene encoding a tumor suppressor protein. In one embodiment, the vector includes a gene encoding a tumor suppressor protein and an inducible promoter controlling the gene encoding a tumor suppressor protein. The tumor suppressor protein may be p53 protein. In another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a nucleic acid sequence encoding an antisense sequence complementary to all or a portion of the gene encoding a tumor suppressor protein. In yet another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a gene which encodes a protein which binds to, and thereby inhibits, the tumor suppressor protein. Such vectors and vector systems enable cells transformed thereby to continue to proliferate such that adequate amounts of infectious viral particles, generated from viral vectors including a gene encoding a tumor suppressor protein, can be harvested for administration to patients.

    NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS
    6.
    发明公开
    NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS 失效
    NON-核苷酸磷酸酯低聚物

    公开(公告)号：EP0880532A1

    公开(公告)日：1998-12-02

    申请号：EP97933585.0

    申请日：1997-01-22

    申请人： PHARMAGENICS, INC.

    发明人： GENTLES, Robert, G. ,  COOK, Alan, F. ,  RUDOLPH, Morris, J. ,  FATHI, Reza

    IPC分类号： C07F9 ,  A61K31 ,  C07B61

    CPC分类号： C07F9/65616 ,  C07F9/1411 ,  C07F9/143 ,  C07F9/145 ,  C07F9/2408 ,  C07F9/2416 ,  C07F9/242 ,  C07F9/5728 ,  C07F9/582 ,  C07F9/588 ,  C07F9/65062 ,  C07F9/650958 ,  C07F9/6539 ,  C07F9/65515 ,  C07F9/6561 ,  C40B40/00 ,  Y02P20/55

    摘要： A phosphorus ester oligomer having structure (I) wherein A can be the same or different in each monomeric unit and each is independently selected from the group consisting of oxygen, sulfur, lower alkyl, substituted or unsubstituted alkylamino, substituted or unsubstituted arylamino and aminoalkyl; B1 and B2 can be the same or different and each is independently selected from hydrogen, lower alkyl, a labelling group, a protecting group, a phosphoramidate or a phosphomonoester; R1 can be the same or different in each monomeric unit, and in at least one of the non-nucleotide monomeric units, R1 is independently selected from the group consisting of a condensation product of (i) a non-vicinal diol attached to a hydrogen bond donor functionality; (ii) a hydrogen bond acceptor selected from an ether, a purine or pyrimidine substituted 1,2-diol or a disubstituted heterocycle; (iii) a non-vicinal diol attached to a hydrophobic functionality or a vicinal diol attached to an aliphatic or alicyclic hydrophobic functionality; (iv) a diol attached to a ring substituted anionic functionality and (v) a cationic moiety attached to a non-vicinal or alicyclic diol, any of which can further include a detectable label, and n is at least one. Preferred R1 moieties include condensation products of heterocyclic diols, alicyclic diols, and polycyclic diols. Also the non-nucleotide monomers thereof, combinatorial library mixtures of the oligomers and the use of the oligomers as selective target-binding compounds.

    OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES
    8.
    发明公开
    OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES 失效
    氨基烃膦含寡核苷酸。

    公开(公告)号：EP0641354A1

    公开(公告)日：1995-03-08

    申请号：EP92925362.0

    申请日：1992-11-20

    申请人： PHARMAGENICS, INC.

    发明人： COOK, Alan, F. ,  FATHI, Reza

    IPC分类号： C07H21 ,  C12Q1

    CPC分类号： C07H21/00 ,  C12Q1/6813 ,  C12Q1/6816

    摘要： An oligonucleotide wherein at least one nucleotide unit includes a phosphonate moiety having the structural formula (I) , wherein X is (a), R1 is a hydrocarbon, preferably methylene, and each of R2, R3, and R4 is hydrogen or a hydrocarbon, and each of R2, R3, and R4 may be the same or different. Preferably, X is an aminomethyl moiety. Such oligonucleotides having improved binding capabilities and improved resistance to nucleases. Alternatively, X may be (b) or (c), wherein R1, R2, and R3 are as hereinabove described, and R5 is a detectable marker, thus making such oligonucleotides useful as diagnostic probes.